Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer.
Procedure: conventional surgery
Procedure: radiofrequency ablation
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer|
|Study Start Date:||June 2002|
|Study Completion Date:||February 2004|
- Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in patients with resectable non-small cell lung cancer.
- Determine the treatment-related toxicity in patients treated with this therapy.
- Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients.
OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection.
PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00039507
|United States, Pennsylvania|
|Fox Chase Cancer Center|
|Philadelphia, Pennsylvania, United States, 19111|
|Study Chair:||Walter J. Scott, MD, FACS||Fox Chase Cancer Center|